Not applicableActive Not RecruitingNCT05470218What this trial is testingLeucine, MTOR and AtheroWho this might be right forAtherosclerosis University of Missouri-Columbia 10
Large-scale testing (Phase 3)Study completedNCT00789828What this trial is testingEfficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)Who this might be right forTuberous SclerosisSubependymal Giant Cell Astrocytoma Novartis Pharmaceuticals 117
Testing effectiveness (Phase 2)Study completedNCT02831257What this trial is testingAZD2014 In NF2 Patients With Progressive or Symptomatic MeningiomasWho this might be right forNeurofibromatosis 2Meningioma Massachusetts General Hospital 18
Large-scale testing (Phase 3)Active Not RecruitingNCT04582136What this trial is testingEfficacy and Safety of Sirolimus in Active Systemic Lupus ErythematosusWho this might be right forSystemic Lupus Erythematosus Chinese SLE Treatment And Research Group 146
Early research (Phase 1)Study completedNCT01548807What this trial is testingPhase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following ProstatectomyWho this might be right forProstate Cancer Patients With Detectable PSA Following Prostatectomy Abramson Cancer Center at Penn Medicine 19
Early research (Phase 1)Looking for participantsNCT07369505What this trial is testingSapu003 in Advanced mTOR-sensitive Solid TumorsWho this might be right forBreast Cancer MetastaticRenal Cell Carcinoma (RCC)Neuroendocrine Tumors+2 more SAPU NANO (US) LLC 27
Not applicableLooking for participantsNCT05233722What this trial is testingMTOR as Mediator of Insulin Sensitivity StudyWho this might be right forInsulin Sensitivity University of Copenhagen 10
Not applicableEnded earlyNCT05571670What this trial is testingBile Acids in Acute Insulin ResistanceWho this might be right forPI3K Gene MutationAKT Gene MutationMTOR Gene Mutation+2 more Columbia University 3
Testing effectiveness (Phase 2)Study completedNCT00411619What this trial is testingEverolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexWho this might be right forTuberous SclerosisSubependymal Giant Cell Astrocytoma Children's Hospital Medical Center, Cincinnati 28
Testing effectiveness (Phase 2)Study completedNCT01520103What this trial is testingStudy to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast CancerWho this might be right forHer2-negative Metastatic Breast CancerHer2-negative Locally Advanced Breast Cancer AIO-Studien-gGmbH 139
Testing effectiveness (Phase 2)Study completedNCT03433183What this trial is testingSARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsWho this might be right forMalignant Peripheral Nerve Sheath TumorsNeurofibromatosis 1 Sarcoma Alliance for Research through Collaboration 21
Testing effectiveness (Phase 2)Ended earlyNCT02644122What this trial is testingSF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway GenesWho this might be right forMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Ezra Cohen 1
Not applicableStudy completedNCT01632605What this trial is testingThe Vienna RAP Pilot StudyWho this might be right forADPKD Medical University of Vienna 8
Testing effectiveness (Phase 2)Study completedNCT01026792What this trial is testingTemsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By SurgeryWho this might be right forCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma+5 more National Cancer Institute (NCI) 38
Not applicableApproved For MarketingNCT03817515What this trial is testingExpanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway ActivationWho this might be right forPEComa, MalignantTSC1TSC2+1 more Aadi Bioscience, Inc.
Testing effectiveness (Phase 2)Study completedNCT05781698What this trial is testingRepurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative ColitisWho this might be right forInflammatory Bowel Diseases Tanta University 60
Early research (Phase 1)Study completedNCT01152801What this trial is testingSafety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerWho this might be right forMetastatic Renal Cell Carcinoma Novartis Pharmaceuticals 64
Testing effectiveness (Phase 2)Looking for participantsNCT06789900What this trial is testingEverolimus and/or Exercise to Prevent Bone Loss in Postmenopausal WomenWho this might be right forPostmenopausal Women Odense University Hospital 136
Not applicableStudy completedNCT01649609What this trial is testingUsing mTOR Inhibitors in the Prevention of BK NephropathyWho this might be right forBK ViremiaBK Nephropathy Columbia University 40
Very early researchWithdrawnNCT04019769What this trial is testingGlutamine Supplementation in People With Immune DysregulationWho this might be right forEczemaMTOROC1 Signaling National Institute of Allergy and Infectious Diseases (NIAID)